What is accelerated approval, and what post-marketing requirements typically accompany it?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Multiple Choice

What is accelerated approval, and what post-marketing requirements typically accompany it?

Accelerated approval is a regulatory route for serious or life-threatening diseases that lets a drug be approved based on a surrogate endpoint likely to predict clinical benefit, rather than on final direct outcomes. The idea is to get potentially beneficial therapies to patients faster when waiting for long-term results would be detrimental. Post-marketing requirements for this pathway typically include confirming the benefit with one or more follow-up, or confirmatory, trials after approval. These trials are intended to verify that the surrogate endpoint truly translates into real clinical improvement. Timelines are often set, and if the confirmatory studies don’t confirm benefit or reveal new safety concerns, the FDA can withdraw approval or require label changes. Ongoing safety monitoring and risk-management measures are also part of the process, and the labeling will reflect the surrogate endpoint that supported approval. The other descriptions don’t fit: standard approval needs full efficacy data before marketing; post-marketing surveillance cannot replace the requirement for confirmatory trials in this pathway; and accelerated approval is not limited to dietary supplements.

Accelerated approval is a regulatory route for serious or life-threatening diseases that lets a drug be approved based on a surrogate endpoint likely to predict clinical benefit, rather than on final direct outcomes. The idea is to get potentially beneficial therapies to patients faster when waiting for long-term results would be detrimental.

Post-marketing requirements for this pathway typically include confirming the benefit with one or more follow-up, or confirmatory, trials after approval. These trials are intended to verify that the surrogate endpoint truly translates into real clinical improvement. Timelines are often set, and if the confirmatory studies don’t confirm benefit or reveal new safety concerns, the FDA can withdraw approval or require label changes. Ongoing safety monitoring and risk-management measures are also part of the process, and the labeling will reflect the surrogate endpoint that supported approval.

The other descriptions don’t fit: standard approval needs full efficacy data before marketing; post-marketing surveillance cannot replace the requirement for confirmatory trials in this pathway; and accelerated approval is not limited to dietary supplements.

More practice questions